Merck and a plaintiff have paused a trial over alleged injuries from the HPV vaccine Gardasil, with ties to HHS Secretary ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...
Merck and a plaintiff have paused a trial over potential Gardasil injuries, with ties to Health Secretary Robert F. Kennedy Jr. The trial resumes in September. Kennedy, involved in mass litigation ...
The Associated Press - Business News on MSN14d
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in ChinaShares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.
Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading ...
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results